Juvenile Idiopathic Arthritis (JIA) Recruiting Phase 2 Trials for Sarilumab (DB11767)

Also known as: Arthritis, Juvenile Idiopathic / Juvenile Idiopathic Arthritis / Arthritis, Juvenile / Juvenile Arthritis / Juvenile seropositive arthritis

IndicationStatusPhase
DBCOND0056190 (Juvenile Idiopathic Arthritis (JIA))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02991469A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)Treatment
NCT02776735An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)Treatment